{"id":389032,"date":"2024-11-15T00:00:00","date_gmt":"2024-11-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0010-2024-biopharma-atopic-dermatitis-atopic-eczema-disease-landscape-forecast-g7-2024\/"},"modified":"2026-04-24T05:13:33","modified_gmt":"2026-04-24T05:13:33","slug":"dlsfim0010-2024-biopharma-atopic-dermatitis-atopic-eczema-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0010-2024-biopharma-atopic-dermatitis-atopic-eczema-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical therapies are often effective for mild disease but have suboptimal safety, tolerability, and compliance. The upheaval in the AD market began with the 2017 launches of Sanofi \/ Regeneron\u2019s injectable biologic Dupixent and Pfizer\u2019s nonsteroidal topical cream Eucrisa. Since then, multiple agents have been approved, including oral JAK inhibitors (Eli Lilly\u2019s Olumiant, AbbVie\u2019s Rinvoq, and Pfizer\u2019s Cibinqo); nonsteroidal topical agents (Japan Tobacco\u2019s Corectim, Incyte\u2019s Opzelura, Otsuka \/ Acrotech Biopharma\u2019s Moizerto, Arcutis\u2019s Zoryve, and Dermavant \/ Japan Tobacco \/ Torii\u2019s Vtama); an IL-31 inhibitor (Galderma \/ Maruho\u2019s Mitchga), and IL-13 inhibitors (Leo Pharma\u2019s targeted biologic Adbry \/ Adtralza and Eli Lilly \/ Almirall\u2019s Ebglyss). This report provides a comprehensive analysis of AD patient populations, current disease management, unmet needs, and the potential of current and emerging drugs.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What are the mild, moderate, and severe AD subpopulation sizes, and how will they change by 2033? How well are they served by current AD therapies?<\/li>\n<li>How have Dupixent and other biologics been incorporated into the AD treatment algorithm? What market niches are oral JAK inhibitors (e.g., Cibinqo, Rinvoq, Olumiant), topicals (e.g., Corectim, Opzelura, Moizerto, Zoryve, Vtama), and other biologics (e.g., Adbry \/ Adtralza, Mitchga, Ebglyss) beginning to occupy?<\/li>\n<li>What therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?<\/li>\n<li>What are the greatest unmet needs in the treatment of AD, and to what degree will therapies in the pipeline address these needs?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan<\/p>\n<p>Primary research: 16 country-specific interviews with thought leaders; supported by survey data collected for this and other Clarivate research<\/p>\n<p>Epidemiology: Diagnosed and drug-treated prevalence of AD by country, 12-month total and diagnosed prevalence of AD by severity<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key AD therapies through 2033, segmented by brands \/ generics, disease severity, and pediatric \/ adult subpopulations<\/p>\n<p>Drug treatments: Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389032","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389032\/revisions"}],"predecessor-version":[{"id":575888,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389032\/revisions\/575888"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}